Rezolute

Rezolute is advancing therapies for serious rare diseases.

[Rezolute @rezolutebio]

We’re pleased to announce four presentations at the Annual Meeting of the Endocrine Society (ENDO) being held in Chicago, IL later this month, including one oral and three poster presentations.

Full presentation details: https://t.co/kuDrfZGwzv

#ENDO2026 #CongenitalHI #TumorHI

[Rezolute @rezolutebio]

This week, we'll be at the @Jefferies Global Healthcare Conference, where our leadership team will discuss the transformative potential of ersodetug for patients with #hyperinsulinism.

Watch our fireside chat on Thursday, June 4 at 3:45 PM EDT here: https://t.co/Ritb4qlLaj

[Rezolute @rezolutebio]

Today we announced positive interim data from our Phase 3 upLIFT study of ersodetug in tumor hyperinsulinism. The study is now 50% enrolled, and 6 of 8 participants have already met the responder criterion for the study’s primary endpoint.

Learn more: https://t.co/aF2zI9yPiN

[Rezolute @rezolutebio]

"Together for Parents" — this year's #GlobalDayOfParents theme — reminds us that no family should face #raredisease alone.

Thank you @UNICEF for highlighting the realities of caregiving. Learn more about the Global Day of Parents: https://t.co/rbf0HyRQti

#Hyperinsulinism

[Rezolute @rezolutebio]

Stories from families living with #hyperinsulinism drive us forward.

We’re working toward creating a different world - one where patients and caregivers no longer live in fear of unpredictable hypoglycemic lows.

Learn more: https://t.co/Z4CtOzYu1J

#Rezolute #CongenitalHI

[Rezolute @rezolutebio]

Today we celebrate #ClinicalTrialsDay and honor the families and professionals driving critical research forward.

Thank you to the study participants, research professionals, and clinicians advancing medicine.

Learn more about our clinical trials here: https://t.co/fiPdOVoZ4V

[Rezolute @rezolutebio]

We're excited to participate in the @HCWCO #BioConnect Investor Conference in New York this week.

If you’re attending, we look forward to connecting to share updates on the exciting milestones ahead for our two late-stage #hyperinsulinism programs.

#congenitalHI #tumorHI

[Rezolute @rezolutebio]

Navigating #hyperinsulinism (HI) comes with challenges no one should face alone—that’s why we’re here to support and stay connected. Be sure to sign up for 𝘛𝘩𝘦 𝘙𝘦𝘻𝘰𝘭𝘶𝘵𝘪𝘰𝘯 and look out for our May edition.

Subscribe: https://t.co/nlUZfyP9wG

#CongenitalHI #TumorHI

[Rezolute @rezolutebio]

We’re looking forward to @NCFCancer's Patient Conference this Saturday, where people living with #neuroendocrinecancer and their caregivers will meet with leading #cancer experts from Emory University, UAB, and Vanderbilt University.

Learn more: https://t.co/UiY9HeuOZL

[Rezolute @rezolutebio]

Today we provided financial results and a business update for fiscal Q3 2026.

Learn more about our progress advancing care for patients living with congenital and tumor #hyperinsulinism.

Read the full release: https://t.co/xEteO1Q47h

#raredisease #congenitalHI #tumorHI

[Rezolute @rezolutebio]

In May, we recognize #NationalCancerResearchMonth by honoring researchers and clinicians advancing #cancer care. We're grateful for their work, and we’re proud to contribute through our efforts to develop a therapy for tumor #hyperinsulinism.

Learn more: https://t.co/kUAbbNrlJ5

[Rezolute @rezolutebio]

This week, @congenitalhi is gathering families, clinicians, researchers, and advocacy leaders to exchange insights about caring for and living with congenital #hyperinsulinism (cHI).

We’re proud to sponsor this special event that helps strengthen the vibrant #cHI community.

[Rezolute @rezolutebio]

To the #nurses advancing care around the world: thank you for your commitment, advocacy, and heart. You make a profound difference in the lives of the families you serve.

#ThePowerOfNurses #IND2026 #OurNursesOurFuture #NursesLightUpTheSky

[Rezolute @rezolutebio]

Today at the Pediatric Endocrine Society (PES) Annual Meeting, Principal Investigator Diva De Leon-Crutchlow presented results from the Phase 3 sunRIZE study of ersodetug in congenital #hyperinsulinism (#cHI).

Learn more: https://t.co/5GqgrP5GNW

#PES2026

[Rezolute @rezolutebio]

This week, hundreds of nurses are gathering for the #PENS2026 conference in Columbus, OH. These professionals provide amazing care and advocate for better outcomes in congenital #hyperinsulinism every day.

To PENS and pediatric endo nurses: Thank you for your life-changing work.

[Rezolute @rezolutebio]

Tumor #hyperinsulinism means living in fear of the next unpredictable, life-threatening hypoglycemic episode.

At Rezolute, we're working to develop a safe, effective therapy for patients, because everyone deserves a life that isn’t defined by fear.

More: https://t.co/UinxhNn6Kx

[Rezolute @rezolutebio]

We’re pleased to announce that results from the Phase 3 sunRIZE study of ersodetug in #congenitalHI have been accepted for an oral presentation at the Pediatric Endocrine Society (PES) Annual Meeting later this month.

Read more: https://t.co/R1VyTgkRgY

#Hyperinsulinism

[Rezolute @rezolutebio]

We're grateful to @RareDiseases for hosting the Rare Disease Scientific Symposium in Arlington this week. It was inspiring to connect with leaders united around an essential goal: advancing innovation in #raredisease research.

#NORDSymposium #Rezolute #congenitalHI #tumorHI

[Rezolute @rezolutebio]

Breakthroughs in #raredisease happen when companies, regulators, HCPs, and advocacy groups collaborate.

Our CEO Nevan Charles Elam spoke with @biospace to discuss our March FDA meeting and potential path forward for ersodetug in #congenitalHI.

Read: https://t.co/HtosoYImTy

[Rezolute @rezolutebio]

We’re proud to support the Neuroendocrine Cancer Awareness Network’s 2026 NET Cancer Patient Conference in Tucson, a space for #NET patients, caregivers, and experts to connect, learn, and shape the future of care together.

Register for free tickets: https://t.co/pRg4s3a5dJ